| Health / Medical Topics |
Angiogenesis Inhibitor JI-101
An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis. (NCI Thesaurus)
YOU MAY ALSO LIKE
An adenovirus encoding an endothelial cell-specific, murine pre-proendothelin-1 (PPE-1) promoter and a Fas-based chimeric death receptor with potential anti-angiogenic activity. Endothelial cell-specific…
A drug or substance that keeps new blood vessels from forming. In cancer treatment, angiogenesis inhibitors may prevent the growth of new…
An angiogenesis inhibitor that acts by blocking the action of endogenous pro-angiogenic substance(s).
Blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This process is caused by…
A disorder characterized by lymphoid hyperplasia in the lymph nodes. There are two histologic variants recognized: the hyaline-vascular type and the plasma…
A rare disorder in which benign (not cancer) growths form in lymph node tissue. There are two main ways that angiofollicular lymph…
